NCT03786484 is a Phase 1 clinical trial of PBF-999 in Cancer, sponsored by Palobiofarma SL.

Who is sponsoring NCT03786484?

NCT03786484 is sponsored by Palobiofarma SL.

What drugs are being tested in NCT03786484?

Interventions in NCT03786484: PBF-999.

Is NCT03786484 still recruiting?

NCT03786484 is currently completed. Last updated 26 January 2023.

Last reviewed 2023-01-26 · How we verify

NCT03786484

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of PBF-999 in Solid Tumour Advanced Cancer

Completed Phase 1 Last updated 26 January 2023

What this trial tests

Phase 1 trial testing PBF-999 in Cancer in 54 participants. Completed in 30 June 2022.

Timeline

1 October 2017

Primary endpoint
30 June 2022

30 June 2022

Quick facts

Lead sponsor	Palobiofarma SL
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	54
Start date	1 October 2017
Primary completion	30 June 2022
Estimated completion	30 June 2022
Sites	1 location across Spain

Drugs / interventions tested

PBF-999 — full drug profile →

Conditions studied

Cancer — all drugs for Cancer →

Sponsor

Palobiofarma SL — full company profile →

Who can join

Eligibility, any sex, with Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Multicentric phase I (dose escalation plus expansion) clinical trial of PBF-999 in patients with immunotherapy naïve and pretreated solid tumors to evaluate the safety, tolerability and preliminary efficacy of the compound

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

CD39/CD73/A2AR pathway and cancer immunotherapy.
Xia C, Yin S, To KKW, Fu L. · · 2023 · cited 230× · PMID 36859386 · DOI 10.1186/s12943-023-01733-x
Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy.
Augustin RC, Leone RD, Naing A, Fong L, et al · · 2022 · cited 103× · PMID 35135866 · DOI 10.1136/jitc-2021-004089
Current Advances of Nitric Oxide in Cancer and Anticancer Therapeutics.
Mintz J, Vedenko A, Rosete O, Shah K, et al · · 2021 · cited 103× · PMID 33513777 · DOI 10.3390/vaccines9020094
Inhibition of the Adenosine Pathway to Potentiate Cancer Immunotherapy: Potential for Combinatorial Approaches.
Thompson EA, Powell JD. · · 2021 · cited 61× · PMID 32903139 · DOI 10.1146/annurev-med-060619-023155
Targeting purinergic pathway to enhance radiotherapy-induced immunogenic cancer cell death.
Bao X, Xie L. · · 2022 · cited 54× · PMID 35836249 · DOI 10.1186/s13046-022-02430-1
PDE10A Inactivation Prevents Doxorubicin-Induced Cardiotoxicity and Tumor Growth.
Chen S, Chen J, Du W, Mickelsen DM, et al · · 2023 · cited 52× · PMID 37232184 · DOI 10.1161/circresaha.122.322264
Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules.
Bondarev AD, Attwood MM, Jonsson J, Chubarev VN, et al · · 2022 · cited 52× · PMID 36506513 · DOI 10.3389/fphar.2022.1057083
Small-molecule agents for cancer immunotherapy.
Wang F, Fu K, Wang Y, Pan C, et al · · 2024 · cited 41× · PMID 38486980 · DOI 10.1016/j.apsb.2023.12.010

Verify or expand the search:

Other recruiting trials for Cancer

Currently open trials in the same condition.

NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors · NA · recruiting
NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy · NA · recruiting
NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients. · NA · recruiting
NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety · NA · recruiting

Other Palobiofarma SL trials

Trials by the same sponsor.

NCT05262218 — Therapeutic Effect of PBF-680 in Patients With COPD · Phase 2 · completed
NCT03798236 — Study to Assess the Safety and Tolerability of PBF-1650 in Healthy Volunteers. · Phase 1 · completed
NCT03274479 — PBF-1129 in Patients With NSCLC · Phase 1 · unknown
NCT03773952 — Safety and Efficacy of PBF-677 in Ulcerative Colitis Patients · Phase 2 · completed
NCT03774290 — Study to Investigate the Effect of PBF-680 on Forced Expiratory Volume in 1 Second (FEV1) in Asthmatic Patients · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03786484 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Palobiofarma SL
Last refreshed: 26 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03786484.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing